Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

A role for adsorption in lead leachability from MSWI bottom ASH.

Chaspoul FR, Le Droguene MF, Barban G, Rose JC, Gallice PM.

Waste Manag. 2008;28(8):1324-30. Epub 2007 Sep 18.

PMID:
17881209
2.

Polyamines secreted by cancer cells possibly account for the impairment of the human erythrocyte sodium pump activity.

Villano PJ, Gallice PM, Nicoara AE, Honore SG, Owczarczak K, Favre RG, Briand CM.

Cell Mol Biol (Noisy-le-grand). 2001 Mar;47(2):305-12.

PMID:
11355005
3.

Sodium pump and Na+/H+ antiport restoration in erythrocytes from cancer patients in remission.

Kovacic HN, Gallice PM, Nicoara AE, Mordoff RI, Favre RG, Crevat AD.

Oncol Res. 1998;10(6):333-9.

PMID:
9848104
4.

A non ouabain-like inhibitor of the sodium pump in uremic plasma ultrafiltrates and urine from healthy subjects.

Gallice PM, Kovacic HN, Brunet PJ, Berland YF, Crevat AD.

Clin Chim Acta. 1998 May 25;273(2):149-60.

PMID:
9657345
5.

Impairment of sodium pump and Na+/H+ antiport in erythrocytes isolated from cancer patients.

Borg AL, Gallice PM, Kovacic HN, Nicoara AE, Favre RG, Crevat AD.

Cancer Res. 1996 Feb 1;56(3):511-4.

6.

Ascorbic acid derivatives in two different fractions of uremic toxins.

Gallice PM, Monti JP, Braguer DL, Baz M, Elsen RE, Berland YF, Crevat AD.

Int J Artif Organs. 1991 Dec;14(12):754-8.

PMID:
1783448
7.

Scaling up in isolation of medium-size uraemic toxins.

Gallice PM, Crevat AD, Berland YF.

J Chromatogr. 1991 Feb 22;539(2):449-53.

PMID:
2045455
8.

Identification of an ascorbic acid metabolite among "uremic middle molecules".

Gallice PM, Monti JP, Braguer DL, Monti HM, Elsen RE, Berland YF, Crevat AD.

Clin Chem. 1990 Jul;36(7):1369-72.

Supplemental Content

Loading ...
Support Center